Weixiang Zhan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Weixiang Zhan has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Jianwei Zhang
Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China
2 shared publications - Runkai Cai
Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
2 shared publications - Yang Fu
Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
2 shared publications - Yanhong Deng
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
2 shared publications Chenxu Guo
Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
1 shared publication- Chenxu Guo
Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
1 shared publication
Latest Publications
- Open Access
- 19 August 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
RMI2 depletion recovers cGAS-STING signaling to enhance immunotherapy in colorectal cancer
Microsatellite-stable (MSS) colorectal cancers (CRCs) are largely refractory to immune checkpoint inhibitors (ICIs) due to immunologically “cold” tumor microenvironments (TMEs) characterized by limited T-cell infiltration. While RecQ-mediated genome instability 2 (RMI2) is known for regulating DNA repair, its role in anti-tumor immunity remains unclear. Here, we demonstrate that RMI2 deficiency impairs homologous recombination repair, causing cytosolic DNA accumulation, cGAS-STING pathway activation, and type I interferon signaling that boosts anti-tumor immunity. Notably, RMI2 knockout in mice synergizes with PD-1 blockade and fluorouracil to induce robust tumor regression and prolonged survival. Our data reveal that RMI2 loss derepresses the cGAS-STING pathway by disrupting DNA repair homeostasis, thereby reversing immune evasion. This paradigm shift converts MSS CRCs into “hot” tumors and renders them responsive to ICI therapy, establishing RMI2 inhibition as a novel therapeutic avenue.
- 19 August 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessRMI2 depletion recovers cGAS-STING signaling to enhance immunotherapy in colorectal cancer
Microsatellite-stable (MSS) colorectal cancers (CRCs) are largely refractory to immune checkpoint inhibitors (ICIs) due to immunologically “cold” tumor microenvironments (TMEs) characterized by limited T-cell infiltration. While RecQ-mediated genome instability 2 (RMI2) is known for regulating DNA repair, its role in anti-tumor immunity remains unclear. Here, we demonstrate that RMI2 deficiency impairs homologous recombination repair, causing cytosolic DNA accumulation, cGAS-STING pathway activation, and type I interferon signaling that boosts anti-tumor immunity. Notably, RMI2 knockout in mice synergizes with PD-1 blockade and fluorouracil to induce robust tumor regression and prolonged survival. Our data reveal that RMI2 loss derepresses the cGAS-STING pathway by disrupting DNA repair homeostasis, thereby reversing immune evasion. This paradigm shift converts MSS CRCs into “hot” tumors and renders them responsive to ICI therapy, establishing RMI2 inhibition as a novel therapeutic avenue.
- Open Access
PTEN deficiency impairs MHC-I-mediated tumour immunity via NRF2-dependent autophagy in microsatellite stable colorectal cancer
Background: Immune checkpoint blockade (ICB) has limited efficacy in microsatellite stable (MSS) colorectal cancer (CRC) due to an immunosuppressive tumour microenvironment. Although loss of phosphatase and tensin homologue (PTEN) occurs in 19–36% of MSS CRC cases, its specific role in driving immune exclusion and ICB resistance remains elusive. Objective: To investigate whether PTEN deficiency promotes resistance to ICB in MSS CRC. Design: An integrative analysis of clinical cohort and The Cancer Genome Atlas (TCGA) database was performed to establish the correlation between PTEN expression and therapeutic response. Single-cell RNA sequencing and flow cytometry were used to identify changes in the tumour immune microenvironment. Immunohistochemistry, mass spectrometry, co-immunoprecipitation and confocal microscopy were employed to dissect the non-canonical function of PTEN. Results: PTEN low expression was strongly associated with reduced CD8 + T-cell infiltration and poor survival in patients receiving ICB. Mechanistically, we identified a non-canonical function of PTEN that physically interacts with and stabilises KEAP1 via the C2 domain, shielding KEAP1 from p62-mediated degradation. Consequently, PTEN deficiency promoted KEAP1 degradation and subsequent NRF2 hyperactivation, which transcriptionally upregulated selective-autophagy machinery, thereby driving the selective lysosomal degradation of major histocompatibility complex (MHC)-I. This process abolished CD8 + T-cell recognition and effector functions, resulting in immune evasion. Crucially, pharmacological inhibition of NRF2 with ML385 restored cell surface MHC-I levels and sensitised PTEN-deficient tumours to anti-programmed cell death protein 1 therapy. Conclusions: PTEN deficiency promotes immune evasion in MSS CRC via an NRF2-dependent axis that triggers autophagy-mediated degradation of MHC-I. Targeting NRF2 represents a promising strategy to enhance the efficacy of immunotherapy in PTEN-deficient MSS CRC.
Open AccessPTEN deficiency impairs MHC-I-mediated tumour immunity via NRF2-dependent autophagy in microsatellite stable colorectal cancer
Background: Immune checkpoint blockade (ICB) has limited efficacy in microsatellite stable (MSS) colorectal cancer (CRC) due to an immunosuppressive tumour microenvironment. Although loss of phosphatase and tensin homologue (PTEN) occurs in 19–36% of MSS CRC cases, its specific role in driving immune exclusion and ICB resistance remains elusive. Objective: To investigate whether PTEN deficiency promotes resistance to ICB in MSS CRC. Design: An integrative analysis of clinical cohort and The Cancer Genome Atlas (TCGA) database was performed to establish the correlation between PTEN expression and therapeutic response. Single-cell RNA sequencing and flow cytometry were used to identify changes in the tumour immune microenvironment. Immunohistochemistry, mass spectrometry, co-immunoprecipitation and confocal microscopy were employed to dissect the non-canonical function of PTEN. Results: PTEN low expression was strongly associated with reduced CD8 + T-cell infiltration and poor survival in patients receiving ICB. Mechanistically, we identified a non-canonical function of PTEN that physically interacts with and stabilises KEAP1 via the C2 domain, shielding KEAP1 from p62-mediated degradation. Consequently, PTEN deficiency promoted KEAP1 degradation and subsequent NRF2 hyperactivation, which transcriptionally upregulated selective-autophagy machinery, thereby driving the selective lysosomal degradation of major histocompatibility complex (MHC)-I. This process abolished CD8 + T-cell recognition and effector functions, resulting in immune evasion. Crucially, pharmacological inhibition of NRF2 with ML385 restored cell surface MHC-I levels and sensitised PTEN-deficient tumours to anti-programmed cell death protein 1 therapy. Conclusions: PTEN deficiency promotes immune evasion in MSS CRC via an NRF2-dependent axis that triggers autophagy-mediated degradation of MHC-I. Targeting NRF2 represents a promising strategy to enhance the efficacy of immunotherapy in PTEN-deficient MSS CRC.